Lexaria Bioscience (LEXX) said Tuesday that an oral form of tirzepatide processed through its DehydraTECH drug delivery platform caused 47% fewer adverse events than Eli Lilly's (LLY) injectable Zepbound.

The company said partial final results of its study comparing the two versions showed that the oral DehydraTECH-tirzepatide version produced 20 adverse events compared with the injection's 38 adverse events.

Both versions produced "similarly increased levels of insulin from baseline" at the end of the eight-day study of nine participants, while blood glucose reductions from each version were comparable, Lexaria Bioscience added.

Additional results from the study are still undergoing analysis and the company said it plans to add a fifth arm to evaluate DehydraTECH-tirzepatide in an oral capsule.

Shares of Lexaria Bioscience were down more than 11% in early Tuesday trading.

Price: 1.87, Change: -0.19, Percent Change: -9.22